DK1066376T3 - Svækkede bakterier ved hjælp af en ikke-reverterende mutation i hver af AROC-, OMPF- og OMPC-generne, der er anvendelige i vacciner - Google Patents

Svækkede bakterier ved hjælp af en ikke-reverterende mutation i hver af AROC-, OMPF- og OMPC-generne, der er anvendelige i vacciner

Info

Publication number
DK1066376T3
DK1066376T3 DK99911949T DK99911949T DK1066376T3 DK 1066376 T3 DK1066376 T3 DK 1066376T3 DK 99911949 T DK99911949 T DK 99911949T DK 99911949 T DK99911949 T DK 99911949T DK 1066376 T3 DK1066376 T3 DK 1066376T3
Authority
DK
Denmark
Prior art keywords
ompf
aroc
mutation
vaccines
reversing
Prior art date
Application number
DK99911949T
Other languages
English (en)
Inventor
Steven Neville Chatfield
Original Assignee
Acambis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acambis Res Ltd filed Critical Acambis Res Ltd
Application granted granted Critical
Publication of DK1066376T3 publication Critical patent/DK1066376T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C12N15/03Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/65Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
DK99911949T 1998-03-25 1999-03-25 Svækkede bakterier ved hjælp af en ikke-reverterende mutation i hver af AROC-, OMPF- og OMPC-generne, der er anvendelige i vacciner DK1066376T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9806449.6A GB9806449D0 (en) 1998-03-25 1998-03-25 Attenuated bacteria useful in vaccines
PCT/GB1999/000935 WO1999049026A1 (en) 1998-03-25 1999-03-25 Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines
EP99911949A EP1066376B1 (en) 1998-03-25 1999-03-25 Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines

Publications (1)

Publication Number Publication Date
DK1066376T3 true DK1066376T3 (da) 2005-10-03

Family

ID=10829280

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99911949T DK1066376T3 (da) 1998-03-25 1999-03-25 Svækkede bakterier ved hjælp af en ikke-reverterende mutation i hver af AROC-, OMPF- og OMPC-generne, der er anvendelige i vacciner

Country Status (19)

Country Link
US (1) US6902906B1 (da)
EP (1) EP1066376B1 (da)
JP (1) JP4516210B2 (da)
KR (1) KR100628657B1 (da)
AT (1) ATE296881T1 (da)
AU (1) AU763683B2 (da)
CA (1) CA2323576C (da)
CZ (1) CZ301520B6 (da)
DE (1) DE69925585T2 (da)
DK (1) DK1066376T3 (da)
ES (1) ES2244182T3 (da)
GB (1) GB9806449D0 (da)
HU (1) HU225644B1 (da)
NO (1) NO327609B1 (da)
NZ (1) NZ507077A (da)
PL (1) PL196076B1 (da)
PT (1) PT1066376E (da)
WO (1) WO1999049026A1 (da)
ZA (1) ZA200004987B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138237B1 (en) * 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
DK1352245T3 (da) * 2001-01-18 2006-12-18 Univ Newcastle Ventures Ltd Biosensor med kovalent bundne membranspændende proteiner
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US7357935B2 (en) * 2003-05-14 2008-04-15 Wyeth Avian E. coli vaccine for protection against colibacillosis
US7297338B2 (en) * 2003-05-14 2007-11-20 Wyeth Avian vaccine composition for the protection of poultry against disease and infection caused by E. coli and Salmonella
WO2007089205A1 (en) * 2006-02-01 2007-08-09 Sbl Vaccin Ab Colonization factor (cf) antigens of enterotoxigenic escherichia coli in recombinant bacteria
JP2008054614A (ja) * 2006-09-01 2008-03-13 Nippon Inst For Biological Science 鶏大腸菌由来弱毒変異株、鶏大腸菌対策用ワクチン、免疫方法及び鶏用ワクチンベクター
EP2517723B1 (en) 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Compositions and methods of enhancing immune responses
JP2011502165A (ja) * 2007-10-30 2011-01-20 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 鞭毛細菌に対する免疫応答を強化する組成物および方法
NZ585777A (en) 2007-11-01 2012-09-28 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria
EA023058B1 (ru) 2010-01-21 2016-04-29 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас Вакцинные векторы и способы усиления иммунных ответов
KR102007132B1 (ko) 2010-06-09 2019-08-05 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
WO2014037445A1 (en) * 2012-09-05 2014-03-13 Lohmann Animal Health Gmbh Preparation of live vaccines
NZ709154A (en) 2012-12-07 2019-10-25 Elanco Tiergesundheit Ag Preparation of live vaccines
EP3610887B8 (en) 2013-02-14 2024-01-24 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
BR112015023024B1 (pt) 2013-03-15 2022-04-19 The Board Of Trustees Of The University Of Arkansas Vetor de vacina e composições farmacêuticas compreendendo o mesmo
SG11201809686SA (en) 2016-05-03 2018-11-29 Univ Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
EP0441071B1 (en) 1990-02-06 1994-09-21 Institut Pasteur Transformed shigella
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
ES2131069T3 (es) * 1991-03-05 1999-07-16 Wellcome Found Expresion de proteinas recombinantes en bacterias atenuadas.

Also Published As

Publication number Publication date
PT1066376E (pt) 2005-10-31
EP1066376A1 (en) 2001-01-10
ATE296881T1 (de) 2005-06-15
NO327609B1 (no) 2009-08-31
CA2323576A1 (en) 1999-09-30
HUP0105430A2 (hu) 2002-04-29
KR20010042175A (ko) 2001-05-25
JP2002507414A (ja) 2002-03-12
GB9806449D0 (en) 1998-05-27
AU763683B2 (en) 2003-07-31
ES2244182T3 (es) 2005-12-01
DE69925585T2 (de) 2006-07-13
ZA200004987B (en) 2001-10-31
JP4516210B2 (ja) 2010-08-04
AU3045899A (en) 1999-10-18
PL196076B1 (pl) 2007-12-31
EP1066376B1 (en) 2005-06-01
HU225644B1 (en) 2007-05-02
CZ20003470A3 (cs) 2001-07-11
US6902906B1 (en) 2005-06-07
CA2323576C (en) 2010-12-07
NO20004781L (no) 2000-11-08
CZ301520B6 (cs) 2010-03-31
NO20004781D0 (no) 2000-09-25
DE69925585D1 (de) 2005-07-07
PL343246A1 (en) 2001-07-30
NZ507077A (en) 2002-10-25
HUP0105430A3 (en) 2004-10-28
WO1999049026A1 (en) 1999-09-30
KR100628657B1 (ko) 2006-09-26

Similar Documents

Publication Publication Date Title
DK1066376T3 (da) Svækkede bakterier ved hjælp af en ikke-reverterende mutation i hver af AROC-, OMPF- og OMPC-generne, der er anvendelige i vacciner
Brown et al. MlrA, a novel regulator of curli (AgF) and extracellular matrix synthesis by Escherichia coli and Salmonella enterica serovar Typhimurium
Oyston et al. The response regulator PhoP is important for survival under conditions of macrophage-induced stress and virulence in Yersinia pestis
Pukatzki et al. Identification of a conserved bacterial protein secretion system in Vibrio cholerae using the Dictyostelium host model system
Allaway et al. Use of differential fluorescence induction and optical trapping to isolate environmentally induced genes
KR937000640A (ko) 생 백신
ES2129386T1 (es) Vacuna contra influenza.
Sarkar-Tyson et al. Polysaccharides and virulence of Burkholderia pseudomallei
IS8254A (is) örugg stökkbreytt veirubóluefni
Vanloubbeeck et al. The immunology of Leishmania infection and the implications for vaccine development
ATE173166T1 (de) Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
Duplantis et al. Essential genes from Arctic bacteria used to construct stable, temperature-sensitive bacterial vaccines
DK1425038T3 (da) Svækkede bakterier, der er anvendelige i vacciner
Kingsley et al. Functional analysis of Salmonella Typhi adaptation to survival in water
DE60226175D1 (de) Mycobakterieller impfstoff
PT1154791E (pt) Composições e métodos de vacinação contra neisseria
Andoh et al. Comparative virulence of phase I and II Coxiella burnetii in immunodeficient mice
Meyer et al. Virulence of a Salmonella typhimurium OmpD mutant
Lagergård et al. On the evolution of the sexually transmitted bacteria Haemophilus ducreyi and Klebsiella granulomatis
Li et al. Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live meningococci
Krueger et al. Unravelling post‐transcriptional PrmC‐dependent regulatory mechanisms in Pseudomonas aeruginosa
HUP9702355A2 (hu) Avirulens Mycoplasma synoviae, és az ezt tartalmazó vakcina
Berchej et al. Calcium requirement and virulence of Yersinia enterocolitica
GT199900014A (es) Gen de streptomyces avermilitis que dirige la relacion de avermectinas b2: b1.
YU8402A (sh) Gen streptomyces avermitilis koji usmerava odnos b2:b1 avermektina